Ju Hua Yuan

Wuhan Grand Hoyo Co., Ltd. engages in the research, development, and manufacture of the amino acids and their derivatives. Its business scope includes pharmaceutical production; production and sale of food additives; production and sale of feed and feed additives; technology and product development, research, and technical services of bioengineering, new materials, and electronic information; and manufacture and sales of developed product. The company was founded on April 13m 2000 and is headquartered in Wuhan, China.Its products includes Active Pharmaceutical Ingredient (APIs), L-Cysteine and its derivatives, L-Arginine and its derivatives, L-amino acids, Acetyl amino acids, and compound salts of amino acids. The company was founded on April 13m 2000 and is headquartered in Wuhan, China.

Wuhan Grand Hoyo Co., Ltd. engages in the research, development, and manufacture of the amino acids and their derivatives. Its business scope includes pharmaceutical production; production and sale of food additives; production and sale of feed and feed additives; technology and product development, research, and technical services of bioengineering, new materials, and electronic information; and manufacture and sales of developed product. The company was founded on April 13m 2000 and is headquartered in Wuhan, China.Its products includes Active Pharmaceutical Ingredient (APIs), L-Cysteine and its derivatives, L-Arginine and its derivatives, L-amino acids, Acetyl amino acids, and compound salts of amino acids. The company was founded on April 13m 2000 and is headquartered in Wuhan, China.

Wuhan Grand Hoyo Co., Ltd. engages in the research, development, and manufacture of the amino acids and their derivatives. Its business scope includes pharmaceutical production; production and sale of food additives; production and sale of feed and feed additives; technology and product development, research, and technical services of bioengineering, new materials, and electronic information; and manufacture and sales of developed product. The company was founded on April 13m 2000 and is headquartered in Wuhan, China.Its products includes Active Pharmaceutical Ingredient (APIs), L-Cysteine and its derivatives, L-Arginine and its derivatives, L-amino acids, Acetyl amino acids, and compound salts of amino acids. The company was founded on April 13m 2000 and is headquartered in Wuhan, China.

Part of Grand Pharmaceutical Group Ltd., Hubei Bafeng Pharmaceuticals & Chemicals Share Co., Ltd. engages in the production and operation of amino acid API products. The company is based in Enshi, China. The Chinese company was founded in 1997. The CEO is Cheng Ping Cai. Hubei Bafeng Pharmaceuticals & Chemicals Share Co. was acquired by Grand Pharmaceutical Group Ltd. on September 27, 2022 for $39.99 million.

Part of Grand Pharmaceutical Group Ltd., Hubei Bafeng Pharmaceuticals & Chemicals Share Co., Ltd. engages in the production and operation of amino acid API products. The company is based in Enshi, China. The Chinese company was founded in 1997. The CEO is Cheng Ping Cai. Hubei Bafeng Pharmaceuticals & Chemicals Share Co. was acquired by Grand Pharmaceutical Group Ltd. on September 27, 2022 for $39.99 million.

Part of Grand Pharmaceutical Group Ltd., Hubei Bafeng Pharmaceuticals & Chemicals Share Co., Ltd. engages in the production and operation of amino acid API products. The company is based in Enshi, China. The Chinese company was founded in 1997. The CEO is Cheng Ping Cai. Hubei Bafeng Pharmaceuticals & Chemicals Share Co. was acquired by Grand Pharmaceutical Group Ltd. on September 27, 2022 for $39.99 million.

Part of Grand Pharmaceutical Group Ltd., Hubei Bafeng Pharmaceuticals & Chemicals Share Co., Ltd. engages in the production and operation of amino acid API products. The company is based in Enshi, China. The Chinese company was founded in 1997. The CEO is Cheng Ping Cai. Hubei Bafeng Pharmaceuticals & Chemicals Share Co. was acquired by Grand Pharmaceutical Group Ltd. on September 27, 2022 for $39.99 million.

Part of Grand Pharmaceutical Group Ltd., Hubei Bafeng Pharmaceuticals & Chemicals Share Co., Ltd. engages in the production and operation of amino acid API products. The company is based in Enshi, China. The Chinese company was founded in 1997. The CEO is Cheng Ping Cai. Hubei Bafeng Pharmaceuticals & Chemicals Share Co. was acquired by Grand Pharmaceutical Group Ltd. on September 27, 2022 for $39.99 million.